{"schema_version":"secwatch.filing_event.v1","accession":"0001815776-24-000035","form_type":"8-K","ticker":"LENZ","cik":"0001815776","company_name":"LENZ Therapeutics, Inc.","filed_at":"2024-04-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.302831+00:00","generated_at":"2026-06-04T02:55:50.675916+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"LENZ Therapeutics: LNZ100 meets Phase 3 primary endpoint; 71% responder rate at 3 hours","bullets":["Primary endpoint met: 71% of LNZ100 patients achieved ≥3-line improvement in near vision at 3 hours without distance loss (p<0.0001).","Rapid onset: 71% achieved ≥3-line improvement at 30 minutes; long duration: 40% at 10 hours.","No serious treatment-related adverse events in >30,000 treatment days across three trials.","LNZ100 selected as lead candidate; company plans NDA submission to FDA in mid-2024.","Patient survey: 90% reported near vision improvement; 75% would continue use post-study."],"urls":{"canonical":"https://secwatch.observer/filing/0001815776-24-000035","json":"https://secwatch.observer/filing/0001815776-24-000035.json","markdown":"https://secwatch.observer/filing/0001815776-24-000035.md","text":"https://secwatch.observer/filing/0001815776-24-000035.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815776/000181577624000035/0001815776-24-000035-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815776/000181577624000035/lenz-20240403.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T02:55:50.675916+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}